The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Administration of a Sirt1 activating drug to elderly volunteers and cigarette smokers decreased plasma levels of total and LDL-cholesterol.
“Conversely, administration of a Sirt1 activating drug to elderly volunteers and cigarette smokers decreased plasma levels of total and LDL-cholesterol.8,9”
From The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (2015) · cites this paper as [8]
The Results (Exploratory Pharmacodynamic Measures; page unavailable) report decreased total and LDL cholesterol after SRT2104 treatment in elderly volunteers. The Methods (Study Participants, Design and Treatment; page unavailable) explicitly exclude users of tobacco or nicotine products, so this paper does not support the claim about cigarette smokers. (LLM, conf=0.90)
Experimental — accuracy not yet measuredClinical studies with another Sirt1 activator have shown a reduction in plasma total cholesterol and LDL-cholesterol.
“In line with our findings, clinical studies with another Sirt1 activator have shown a reduction in plasma total cholesterol and LDL-cholesterol.8,9”
From The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (2015) · cites this paper as [8]
Sirt1 regulates plasma LDL-cholesterol.
“These studies suggest that Sirt1 regulates plasma LDL-cholesterol.”
From The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (2015) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778
Feige, J. N., Lagouge, M., Canto, C., Strehle, A., Houten, S. M., Milne, J. C., Lambert, P. D., Mataki, C., Elliott, P. J., & Auwerx, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.017 · Cited by 719
Sirt1 Regulates Insulin Secretion by Repressing UCP2 in Pancreatic β Cells
Bordone, L., Motta, M. C., Picard, F., Robinson, A., Jhala, U. S., Apfeld, J., McDonagh, T., Lemieux, M., McBurney, M., Szilvasi, A., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0040031 · Cited by 715
Mooy, J. M., Grootenhuis, P. A., de Vries, H., Kostense, P. J., Popp-Snijders, C., Bouter, L. M., & Heine, R. J. (1996) · Diabetologia · doi:10.1007/bf00418345 · Cited by 344
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Matthews, P. M., Allaire, C., Shoubridge, E. A., Karpati, G., Carpenter, S., & Arnold, D. L. (1991) · Neurology · doi:10.1212/wnl.41.1.114 · Cited by 121
Self-citation
Flagged first, then by citations
Research works printed but not linked: 40
- MC Haigis, 2010, Mammalian sirtuins: biological insights and disease relevance, Annu Rev Pathol, 5, 253, 10.1146/annurev.pathol.4.110807.092250 · DOI · Paper page
- IB Leibiger, 2006, Sirt1: a metabolic master switch that modulates lifespan, Nat Med, 12, 34, 10.1038/nm0106-34 · DOI
- A Camins, 2010, Sirtuin activators: designing molecules to extend life span, Biochim Biophys Acta, 1799, 740, 10.1016/j.bbagrm.2010.06.005 · DOI
- RK Minor, 2011, SRT1720 improves survival and healthspan of obese mice, Sci Rep (Nature), 1, 1
- LK Heilbronn, 2006, Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial, JAMA, 295, 1539, 10.1001/jama.295.13.1539 · DOI · Paper page
- F Picard, 2004, Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma, Nature, 429, 771, 10.1038/nature02583 · DOI
- JA Baur, 2010, Resveratrol, sirtuins, and the promise of a DR mimetic, Mech Ageing Dev, 131, 261, 10.1016/j.mad.2010.02.007 · DOI
- PJ Elliott, 2009, Resveratrol/SRT-501, Drugs Fut, 34, 291, 10.1358/dof.2009.034.04.1360696 · DOI
- VM Nayagam, 2006, SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents, J Biomol Screen, 11, 959, 10.1177/1087057106294710 · DOI
- H Yang, 2007, Design and synthesis of compounds that extend yeast replicative lifespan, Aging Cell, 6, 35, 10.1111/j.1474-9726.2006.00259.x · DOI
- JE Bemis, 2009, Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators, Bioorg Med Chem Lett, 19, 2350, 10.1016/j.bmcl.2008.11.106 · DOI
- E Hoffmann, 2012, Pharmacokinetics and Tolerability of SRT2104, a First-In-Class Small Molecule Activator of SIRT1, after Single and Repeated Oral Administration in Man, Br J Clin Pharmacol
- 1998, Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data, BMJ, 8, 371
- Y-L He, 2007, Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT, J Clin Pharmacol, 47, 633, 10.1177/0091270006299137 · DOI
- DE Larson-Meyer, 2000, 31P MRS measurement of mitochondrial function in skeletal muscle: reliability, force-level sensitivity and relation to whole body maximal oxygen uptake, NMR Biomed, 13, 14, 10.1002/(SICI)1099-1492(200002)13:1<14::AID-NBM605>3.0.CO;2-0 · DOI
- MFH Schocke, 2004, High-energy phosphate metabolism during incremental calf exercise in humans measured by 31 phosphorus magnetic resonance spectroscopy (31P MRS), Magn Reson Imaging, 22, 109, 10.1016/j.mri.2003.07.001 · DOI
- GJ Kemp, 1994, Quantitative interpretation of bioenergetic data from 31P and 1H magnetic resonance spectroscopic studies of skeletal muscle: an analytical review, Magn Reson Q, 10, 43
- DE Larson-Meyer, 2001, Relation between in vivo and in vitro measurements of skeletal muscle oxidative metabolism, Muscle Nerve, 24, 1665, 10.1002/mus.1202 · DOI
- R Hume, 1966, Prediction of lean body mass from height and weight, J Clin Pathol, 19, 389, 10.1136/jcp.19.4.389 · DOI
- A Naressi, 2001, Java-based graphical user interface for the MRUI quantitation package, MAGMA, 12, 141, 10.1007/BF02668096 · DOI
- M Vanderthommen, 2003, A comparison of voluntary and electrically induced contractions by interleaved 1H- and 31P-NMRS in humans, J Appl Physiol, 94, 1012, 10.1152/japplphysiol.00887.2001 · DOI
- NM Rofsky, 1999, Abdominal MR imaging with a volumetric interpolated breath-hold examination, Radiology, 212, 876, 10.1148/radiology.212.3.r99se34876 · DOI
- EL Thomas, 1998, Magnetic resonance imaging of total body fat, J Appl Physiol, 85, 1778, 10.1152/jappl.1998.85.5.1778 · DOI
- Medicine ACoS (2009) ACSM's Guidelines for exercise testing and prescription. Philadelphia, PA: Lippincott, Williams and Wilkins.
- A Rostami-Hodjegan, 2007, Simulation and prediction of in vivo drug metabolism in human populations from in vitro data, Nat Rev Drug Discov, 6, 140, 10.1038/nrd2173 · DOI
- TL Zern, 2003, Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs, J Nutr, 133, 2268, 10.1093/jn/133.7.2268 · DOI
- G-M Do, 2008, Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice, Biochem Biophys Res Commun, 374, 55, 10.1016/j.bbrc.2008.06.113 · DOI
- X Li, 2007, SIRT1 deacetylates and positively regulates the nuclear receptor LXR, Mol Cell, 28, 91, 10.1016/j.molcel.2007.07.032 · DOI
- EL Jacobson, 2012, Niacin: vitamin and antidyslipidemic drug, Subcell Biochem, 56, 37, 10.1007/978-94-007-2199-9_3 · DOI
- B Ponugoti, 2010, SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism, J Biol Chem, 285, 33959, 10.1074/jbc.M110.122978 · DOI
- KM Utzschneider, 2007, Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies, Diabetologia, 50, 2516, 10.1007/s00125-007-0819-5 · DOI
- BJ Gurd, 2011, Nuclear SIRT1 activity, but not protein content, regulates mitochondrial biogenesis in rat and human skeletal muscle, Am J Physiol Regul Integr Comp Physiol, 301, 67, 10.1152/ajpregu.00417.2010 · DOI
- KJ Menzies, 2012, The role of SirT1 in muscle mitochondrial turnover, Mitochondrion, 12, 5, 10.1016/j.mito.2011.03.001 · DOI
- DL Tomlin, 2001, The relationship between aerobic fitness and recovery from high intensity intermittent exercise, Sports Med, 31, 1, 10.2165/00007256-200131010-00001 · DOI · Paper page
- DR Bassett, 2000, Limiting factors for maximum oxygen uptake and determinants of endurance performance, Med Sci Sports Exerc, 32, 70, 10.1097/00005768-200001000-00012 · DOI · Paper page
- RJ Dandurand, 1995, Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels, Chest, 108, 182
- G Layec, 2012, Reduced muscle oxidative capacity is independent of O2 availability in elderly people, Age
- EL Thomas, 2011, Pragmatic study of orlistat 60 mg on abdominal obesity, Eur J Clin Nutr, 65, 1256, 10.1038/ejcn.2011.108 · DOI
- DE Kelley, 2004, Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes, Diabetes Care, 27, 33, 10.2337/diacare.27.1.33 · DOI
- JR Berggren, 2008, Skeletal muscle lipid oxidation and obesity: influence of weight loss and exercise, Am J Physiol Endocrinol Metab, 294, 726, 10.1152/ajpendo.00354.2007 · DOI · Paper page
Cited by
Sorted by citations
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Bonkowski, M. S., & Sinclair, D. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.93 · Cited by 834
Sirtuin activators and inhibitors: Promises, achievements, and challenges
Dai, H., Sinclair, D. A., Ellis, J. L., & Steegborn, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.004 · Cited by 463
“In a study in elderly volunteers (Libri et al., 2012), SRT2104 was well tolerated at doses up to 2,000 mg and produced a decrease in serum cholesterol, LDL levels and triglycerides but had no significant effect in an oral glucose tolerance test.”
BackgroundRepairing mitochondrial dysfunction in disease
Sorrentino, V., Menzies, K. J., & Auwerx, J. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104908 · Cited by 337
Miranda, M. X., van Tits, L. J., Lohmann, C., Arsiwala, T., Winnik, S., Tailleux, A., Stein, S., Gomes, A. P., Suri, V., Ellis, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu095 · Cited by 153
The road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders
Alageel, A., Tomasi, J., Tersigni, C., Brietzke, E., Zuckerman, H., Subramaniapillai, M., Lee, Y., Iacobucci, M., Rosenblat, J. D., Mansur, R. B., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.05.017 · Cited by 45
Roshanravan, B., Liu, S. Z., Ali, A. S., Shankland, E. G., Goss, C., Amory, J. K., Robertson, H. T., Marcinek, D. J., & Conley, K. E. (2021) · PLOS ONE · doi:10.1371/journal.pone.0253849 · Cited by 38
Giovarelli, M., Zecchini, S., Casati, S. R., Lociuro, L., Gjana, O., Mollica, L., Pisanu, E., Mbissam, H. D., Cappellari, O., De Santis, C., et al. (2025) · Cell Death & Disease · doi:10.1038/s41419-025-07595-z · Cited by 12
Metadata
- Authors
- Libri, V., Brown, A. P., Gambarota, G., Haddad, J., Shields, G. S., Dawes, H., Pinato, D. J., Hoffman, E., Elliot, P. J., Vlasuk, G. P., Jacobson, E., Wilkins, M. R., & Matthews, P. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-20
- Volume
- 7
- Issue
- 12
- Pages
- e51395
- ISSN
- 1932-6203
- PMC
- PMC3527451
- Cited by
- 135
- References
- 8
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
